How do I install the Ata Pregnant Ppgl Management skill?

Run npx skillmds@latest add dromlakhani/ata-pregnant-ppgl-management in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Ata Pregnant Ppgl Management safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Ata Pregnant Ppgl Management?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Ata Pregnant Ppgl Management free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Ata Pregnant Ppgl Management?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Ata Pregnant Ppgl Management by dromlakhani

Name: Ata Pregnant Ppgl Management
Rating: 4.2 (5 reviews)
Author: dromlakhani

Ata Pregnant Ppgl Management

Manage pheochromocytoma and paraganglioma in pregnancy by preferring ultrasound or MRI for imaging (avoiding CT/123I-MIBG unless benefits outweigh radiation risks), using selective α-blockers as first-line medical therapy (adding calcium antagonists if needed before delivery), and recommending tumor resection in the second trimester up to 24 weeks gestation when feasible. Triggers include pregnancy with hypertension, headaches, palpitations, or adrenal mass, and the clinician question “How should I manage a pregnant patient with suspected or confirmed pheochromocytoma?”

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Manage pheochromocytoma and paraganglioma in pregnancy

STEP 1 — Gather Information

Obtain maternal vitals, symptom history (hypertension, headaches, palpitations, sweating), biochemical screening (urinary fractionated metanephrines creatinine‑corrected or plasma‑free fractionated metanephrines), gestational age, fetal ultrasound, and maternal imaging (start with abdominal ultrasound; if indeterminate, proceed with MRI without gadolinium).

STEP 2 — Rule In / Rule Out

If fractionated metanephrines are >3× the upper limit of normal and imaging shows an adrenal or extra‑adrenal mass, rule in PPGL; if biomarkers are normal and no mass is identified, rule out PPGL and consider pregnancy‑induced hypertension or other causes.

STEP 3 — Classify or Stratify

Classify by gestational age: first trimester (<14 weeks), second trimester (14–24 weeks), or third trimester (>24 weeks); additionally assess tumor size, location, and resectability (e.g., <5 cm, no invasion).

STEP 4 — Decide

First trimester: initiate selective α‑blocker (e.g., doxazosin 1 mg nightly, titrate to BP <130/80 mmHg); add calcium antagonist (nifedipine or amlodipine) if BP remains uncontrolled; defer surgery until second trimester if feasible.
Second trimester ≤24 weeks and tumor resectable: proceed with laparoscopic adrenalectomy after adequate α‑blockade (≥7‑14 days).
24 weeks or unresectable tumor: continue medical management, avoid β‑blockers for tachycardia unless α‑blockade is established, plan delivery (cesarean section if catecholamines remain high), and schedule postpartum tumor resection.

Clinical Guardrails / Mimics / Pitfalls

Do not use CT or 123I‑MIBG scintigraphy unless the diagnostic benefit clearly outweighs radiation exposure and informed consent is obtained; avoid metyrosine due to insufficient safety data in pregnancy; do not administer β‑blockers before α‑blockade (risk of hypertensive crisis); avoid ARBs, ACE‑Is, and direct renin inhibitors (fetotoxic); treat hypertensive crisis with intravenous phentolamine, not β‑blockers alone.

Concrete Clinical Example

A 28‑year‑old G2P1 at 18 weeks gestation presents with episodic hypertension, frontal headaches, and palpitations. Urinary fractionated metanephrines are 5× ULN. MRI reveals a 3 cm left adrenal mass without invasion. Doxazosin is started at 1 mg nightly and titrated to 4 mg daily, achieving BP 122/78 mmHg. At 20 weeks, after 10 days of α‑blockade, she undergoes uncomplicated laparoscopic left adrenalectomy. She delivers a healthy infant at 38 weeks via vaginal delivery; postpartum pathology confirms a pheochromocytoma.

Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165

---name: ata-pregnant-ppgl-managementdescription: Manage pheochromocytoma and paraganglioma in pregnancy by preferring ultrasound or MRI for imaging (avoiding CT/123I-MIBG unless benefits outweigh radiation risks), using selective α-blockers as first-line medical therapy (adding calcium antagonists if needed before delivery), and recommending tumor resection in the second trimester up to 24 weeks gestation when feasible. Triggers include pregnancy with hypertension, headaches, palpitations, or adrenal mass, and the clinician question “How should I manage a pregnant patient with suspected or confirmed pheochromocytoma?”---# Manage pheochromocytoma and paraganglioma in pregnancy## STEP 1 — Gather InformationObtain maternal vitals, symptom history (hypertension, headaches, palpitations, sweating), biochemical screening (urinary fractionated metanephrines creatinine‑corrected or plasma‑free fractionated metanephrines), gestational age, fetal ultrasound, and maternal imaging (start with abdominal ultrasound; if indeterminate, proceed with MRI without gadolinium). ## STEP 2 — Rule In / Rule OutIf fractionated metanephrines are >3× the upper limit of normal **and** imaging shows an adrenal or extra‑adrenal mass, rule in PPGL; if biomarkers are normal and no mass is identified, rule out PPGL and consider pregnancy‑induced hypertension or other causes. ## STEP 3 — Classify or StratifyClassify by gestational age: first trimester (<14 weeks), second trimester (14–24 weeks), or third trimester (>24 weeks); additionally assess tumor size, location, and resectability (e.g., <5 cm, no invasion). ## STEP 4 — Decide- First trimester: initiate selective α‑blocker (e.g., doxazosin 1 mg nightly, titrate to BP <130/80 mmHg); add calcium antagonist (nifedipine or amlodipine) if BP remains uncontrolled; defer surgery until second trimester if feasible. - Second trimester ≤24 weeks and tumor resectable: proceed with laparoscopic adrenalectomy after adequate α‑blockade (≥7‑14 days). - >24 weeks or unresectable tumor: continue medical management, avoid β‑blockers for tachycardia unless α‑blockade is established, plan delivery (cesarean section if catecholamines remain high), and schedule postpartum tumor resection. ## Clinical Guardrails / Mimics / PitfallsDo not use CT or 123I‑MIBG scintigraphy unless the diagnostic benefit clearly outweighs radiation exposure and informed consent is obtained; avoid metyrosine due to insufficient safety data in pregnancy; do not administer β‑blockers before α‑blockade (risk of hypertensive crisis); avoid ARBs, ACE‑Is, and direct renin inhibitors (fetotoxic); treat hypertensive crisis with intravenous phentolamine, not β‑blockers alone. ## Concrete Clinical ExampleA 28‑year‑old G2P1 at 18 weeks gestation presents with episodic hypertension, frontal headaches, and palpitations. Urinary fractionated metanephrines are 5× ULN. MRI reveals a 3 cm left adrenal mass without invasion. Doxazosin is started at 1 mg nightly and titrated to 4 mg daily, achieving BP 122/78 mmHg. At 20 weeks, after 10 days of α‑blockade, she undergoes uncomplicated laparoscopic left adrenalectomy. She delivers a healthy infant at 38 weeks via vaginal delivery; postpartum pathology confirms a pheochromocytoma. **Source:** Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, doi:10.1507/endocrj.EJ25-0165

Frequently asked questions